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In Vitro Protein Binding of Cefonicid and Cefuroxime in
Adult and Neonatal Sera
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The levels of in vitro protein binding of cefonicid and cefuroxime in human adult and neonatal sera were
compared. Binding parameters for each drug were determined within the concentration range of 25 to 3,000
,ug/ml. Cefonicid exhibited concentration-dependent protein binding in both types of sera, with more extensive
binding in adult serum at all concentrations. Two classes of binding sites were found: a high-affinity, saturable
site and a low-affinity, nonspecific site. Cefuroxime also showed two-class, concentration-dependent protein
binding in adult serum, but binding in neonatal serum was to a single class and was independent of drug
concentration. Parameters for class 1 binding sites for cefonicid indicated one binding site per albumin
molecule in both adult and neonatal sera, with association constants of 7.0 x 104 and 1.3 x 104 M-1,
respectively. These parameters were also derived for cefuroxime in adult serum and were 0.15 and 7.1 x 104
M-1, respectively. In neonatal serum, the combined value (number of binding sites per molecule x equilibrium
association constant) was similar to combined values calculated for class 2 binding sites for cefuroxime in adult
serum and for cefonicid in neonatal serum (287 versus 195 and 261 M-1, respectively). Cephalosporins have
been shown to compete with bilirubin for albumin binding sites. Lower levels of protein binding of cefuroxime
in the therapeutic range may mean a lower potential for drug displacement of bilirubin in neonates, on the basis
of these results. It may be prudent to select less highly protein-bound agents when treating neonatal infections.

Serum protein binding significantly affects the pharmacokinetic and pharmacodynamic behaviors of drugs. Many
drugs bind in vivo to serum proteins, usually albumin,
forming a reversible complex through hydrogen bonding
(18). The proportion of bound drug depends on a number of
factors, including drug and protein concentrations, the affinity of protein for the drug, and the number of protein binding
sites (20). Generally, only unbound drug is pharmacologically active (21); therefore, changes in serum protein binding
can have important effects on clinical outcome.
Protein binding can determine the distribution, tissue
penetration, clearance, and other pharmacokinetic properties of drugs (6, 7, 10, 15). Interactions due to protein binding
may become significant when two or more highly bound
(>90%) agents with a common binding site are combined
(10, 12). The displacement that occurs from competition for
binding sites results in elevated free concentrations of one or
both drugs (12), resulting in increased pharmacological effects or toxicities, increased tissue distribution, increased
clearance, or a combination of these.
Displacement interactions may occur between drugs and
protein-bound endogenous substances, such as bilirubin,
resulting in increased free bilirubin concentrations (4, 11,
16). Such a result is of particular importance in neonates, in
whom the albumin concentration and binding affinity of
albumin for bilirubin are already lower than those in adults

(14). A further reduction in bilirubin binding by competition
for binding sites, resulting in increased levels of unbound
bilirubin, will increase bilirubin penetration into the central
nervous system and may lead to the development of kernicterus. In adults, the levels of plasma protein binding of
cefonicid and cefuroxime have been reported to be 96 and
33%, respectively, at therapeutic concentrations (8, 9).
However, the effect of various drug concentrations on serum
protein binding and differences in the levels of protein
binding of these antibiotics between adult and neonatal
patients have not been well studied. Before we can fully
investigate antibiotic displacement of bilirubin in neonates,
we need to understand better the binding characteristics of
these agents in adult and neonatal sera.
The objectives of this study were (i) to determine the
effects of various drug concentrations on the protein binding
of cefonicid and cefuroxime in pooled adult and neonatal
sera, (ii) to characterize the protein binding parameters for
the antibiotics, and (iii) to compare the protein binding
parameters for cefonicid and cefuroxime in neonatal serum
with those in adult serum.
MATERIALS AND METHODS
Materials. Pooled human neonatal serum was obtained
from umbilical cord samples sent to the hospital laboratory
for routine analysis at the time of birth. Adult serum was
obtained from the blood bank. Serum chemistry profiles,
including albumin and protein concentrations, were determined for a portion of the pooled sera. The serum albumin
concentration in pooled adult serum was 48 g/liter (6.96 x
10-4 M), and that in pooled neonatal serum was 38 g/liter
(5.51 x 10-4 M). Cefazolin (Ancef; SmithKline Beecham),
cefonicid (Monocid; SmithKline Beecham), and cefuroxime
(Zinacef; Glaxo, Inc.) were purchased from the hospital
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pharmacy. Sodium acetate, glacial acetic acid, 8-chlorotheophylline, disodium phosphate, triethylamine, phosphoric
acid, acetonitrile, methanol, and high-pressure liquid chromatography (HPLC)-grade water were obtained from J. T.
Baker (Phillipsburg, N.J.).
Protein binding. A stock solution of each drug was prepared daily. Buffer samples, which served as free-drug
controls for the protein binding studies, were prepared with
aliquots of the drug stock solutions added to Sorenson's
phosphate buffer (pH 7.4). The antibiotic concentrations in
the buffer samples ranged from 2.5 to 5,000 ,ug/ml. Serum
samples were prepared with 2 ml of pooled serum, and
aliquots of the drug stock solutions were added to obtain
final antibiotic concentrations ranging from 25 to 3,000
,ug/ml. High antibiotic concentrations were used to better
characterize the binding of the drugs to serum proteins.
Limitations in assay sensitivity prohibited the assessment of
protein binding at lower drug concentrations. After incubation at room temperature for 30 min, free cefonicid and
cefuroxime were separated from protein-bound drug by use
of an ultrafiltration system with YMT filters (Amicon, Danvers, Mass.). One milliliter of spiked serum at each concentration was placed in the ultrafiltration system and centrifuged (Centra 4; International Equipment Co., Needham
Heights, Mass.) at 3,000 rpm for 6 min, and the ultrafiltrate,
containing free drug, was collected. All assays were done in
duplicate.
Drug analysis. Concentrations of cefuroxime and cefonicid
were assayed by previously published HPLC techniques (3,
5). For cefuroxime, a 0.1 M acetate buffer (pH 3.85)acetonitrile (90%:10%) mobile phase was used with 8-chlorotheophylline as the internal standard. For cefonicid, the
mobile phase consisted of a 0.05 M phosphate buffer (pH
7.2)-methanol-acetonitrile (86%:6%:8%) mixture, and cefazolin was used as the internal standard. Mobile phases were
delivered at a rate of 1.5 ml/min. HPLC analyses were
performed with a Waters 510 pump, a WISP 710B sample
processor, and a Lambda-Max model 481 (Waters, Milford,
Mass.) variable-wavelength UV-visible light absorbance detector set at 254 nm. The analytical column used was a
reversed-phase (C18) column (250 by 4.6 mm; particle size, 5
,um) (Econosphere; Alltech Associates, Deerfield, Ill.).
The standard curves were linear in the antibiotic concentration range of 0.5 to 5,000 ,ug/ml for cefonicid and 1 to
5,000 ,ug/ml for cefuroxime. The lower limits of quantitation
for the assay were 0.5 ,ug/ml for cefonicid and 1 ,ug/ml for
cefuroxime. The intra- and interday coefficients of variation
for the assays were less than 10% for both drugs at all drug
concentrations measured.
Data analysis. The Akaike's Information Criterion (23) and
lack of systematic deviations around fitted curves were used
to select model equations to fit the data. The protein binding
of cefonicid in adult and neonatal sera and the protein
binding of cefuroxime in adult serum were characterized by
the relationship (17)

FB DBI(DB + DF)
=

(1)

where

DB

=

[(N1K1PADF)/(1

+

KlDF) + N2K2PADF

(2)

and FB is the fraction of drug bound; DB, DF, and PA are the
molar concentrations of bound drug, unbound drug, and
albumin, respectively; N is the number of binding sites per
molecule; and K is the equilibrium association constant.
Subscripts 1 and 2 refer to the first and second classes of
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FIG. 1. Cefonicid serum protein binding in adult (0) and neonatal (@) sera. The lines depict the NONLIN least-squares regression
fitting of these data. The open box represents the therapeutic range
(25 to 300 mg/liter) of cefonicid.

binding sites, respectively. The protein binding parameters
N1, K1, and N2K2 were estimated by nonlinear least-squares
regression (13) with equations 1 and 2.
The protein binding of cefuroxime in neonatal serum,
however, was independent of drug concentration and was
characterized by the relationship

FB

=

DB/(DB + DF)

(3)

where

DB = NKPADF
(4)
and the protein binding parameter NK was estimated by
nonlinear least-squares regression (13) with equations 3 and
4.

RESULTS
The fraction of cefonicid bound to serum proteins as a
function of total drug concentration in adult and neonatal
sera is illustrated in Fig. 1. The protein binding of cefonicid
was dependent on drug concentration in both adult and
neonatal sera, although the extent of binding in adult serum
was greater than that in neonatal serum at all concentrations
studied. The extent of serum protein binding decreased with
increasing concentrations of antibiotic. The binding of cefonicid to both adult and neonatal serum proteins was best
described by two classes of binding sites (equations 1 and 2).
The protein binding parameters generated by NONLIN
least-squares regression analysis are presented in Table 1. In
both matrices, cefonicid serum protein binding was characterized by a high-affinity, saturable binding site and a lowaffinity, nonspecific binding site. On the basis of the assumption that cefonicid associates with serum albumin, the
number of high-affinity cefonicid binding sites per molecule
was approximately 1 for both adult and neonatal sera.
However, the equilibrium association constants differed
significantly, with the neonatal binding sites having approximately 19% of the affinity for cefonicid of the adult binding
sites. The combined value for the second class of cefonicid
binding site (N2K2) differed approximately twofold between
adult and neonatal sera. In addition, the albumin concentration in neonatal serum was approximately 20% lower than
that in adult serum.
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TABLE 1. Protein binding parameters for cefonicid and cefuroxime in adult and neonatal sera
M-1
Mb
Klb, l,
Nlb1K,M
N2K2",M

Albumin concn'

Drug and

% Binding

serum

(10-4 M)

Cefonicid
Adult
Neonatal

6.96
5.51

0.93 (0.04)
1.0 (0.08)

7.0 x 104 (2.1 x 104)
1.3 x 104 (0.2 x 104)

537 (34)
261 (52)

31.5-99.9
20.9-90.0

Cefuroxime
Adult
Neonatal

6.96
5.51

0.15 (0.023)

7.1 x 104 (4.4 x 104)

195 (36)
287 (17)

8.8-88.0
10.9-21.9

a The albumin concentrations were measured chemically.
NONLIN least-squares parameter estimate (SE).

b

The protein binding of cefuroxime as a function of total
drug concentration in adult and neonatal sera is shown in
Fig. 2. Concentration-dependent binding was found with
cefuroxime in adult serum (range, 8.8 to 88%), whereas in
neonatal serum, cefuroxime exhibited constant fractional
protein binding over the drug concentration range studied.
The fraction of cefuroxime bound in neonatal serum averaged 15.6 + 3.8% (mean + standard deviation). In adult
serum, the binding of cefuroxime was best described by two
classes of binding sites (equations 1 and 2); however, the
binding of cefuroxime in neonatal serum was best described
by a single, low-affinity binding site (equations 3 and 4). The
serum protein binding parameters for cefuroxime in adult
and neonatal sera are shown in Table 1. In adult serum, the
number of high-affinity binding sites per molecule of albumin
was 0.15. The cefuroxime high-affinity equilibrium association constant was similar to that observed for cefonicid (7.1
x 104 and 7.0 x 104 M-1, respectively). The second class of
cefuroxime binding site in adult serum had a combined value
(N2K2) somewhat lower than that observed for cefonicid
(195 and 537 M-1, respectively). In neonatal serum, a single,
nonsaturable binding site provided the best fit for the cefuroxime protein binding data; hence, only a combined constant (N2K2; Table 1) could be calculated. The N2K2 values
for the low-affinity binding sites were similar in both sera.
DISCUSSION
The purpose of this investigation was to compare the
protein binding of two cephalosporins, cefonicid and cefu1.0
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FIG. 2. Cefuroxime serum protein binding in adult (0) and
neonatal (-) sera. The lines depict the NONLIN least-squares
regression fitting of these data. The open box represents the
therapeutic range (25 to 100 mg/liter) of cefuroxime.

roxime, in adult and neonatal sera. Cefonicid has been
reported to be highly bound to serum proteins (8), while
cefuroxime has been reported to be moderately bound (9).
However, few investigations have examined the serum protein binding of drugs in the neonatal population. The protein
binding of the antibiotics was studied over a wide range of
drug concentrations, including those exceeding therapeutic
levels, to accurately characterize and determine protein
binding parameters. The results of this study demonstrate
notable differences between the binding of these two cephalosporins in adult and neonatal sera.
The binding of cefonicid to both adult and neonatal serum
proteins was highly dependent on drug concentration, with a
decreased fraction of cefonicid being bound as drug concentration increased. Over the cefonicid concentration range of
25 to 3,000 ,g/ml, the percentage of drug bound to serum
proteins decreased from 99.9 to 31.5% and from 90.0 to
20.9% in adult and neonatal sera, respectively. Within the
therapeutic range, binding was independent of drug concentration at lower concentrations (25 to 150 ,ug/ml) but became
nonlinear at higher concentrations (150 to 300 ,ug/ml, Fig. 1).
Cefonicid protein binding in adult serum within the therapeutic range was similar to that reported previously (90 to
98%) (1, 8). Cefonicid was found to bind to a high-affinity,
saturable binding site as well as to a low-affinity site that was
not saturated over the range of drug concentrations studied.
Previous investigations suggested that cephalosporins associate with a single high-affinity binding site on serum albumin
(19). The results of the present study examining the binding
of cefonicid support these earlier findings. However, a
second class of low-affinity binding site was also detected.
This second class of binding site was observed in the present
study because of the wide range of drug concentrations used.
The fraction of cefonicid bound to neonatal serum proteins
was smaller than that bound to adult serum proteins at all
drug concentrations studied. This difference was relatively
constant, with the fraction bound in neonatal serum being
approximately 0.1 lower than that in adult serum. We
attribute the lower level of fractional binding of cefonicid in
neonatal serum to the 20% lower serum albumin concentration and the 80% lower equilibrium association constant in
neonatal serum. The lower association constant in neonatal
serum may be due to conformational differences between
neonatal and adult albumin. Alternatively, the lower association constant may result from the presence of endogenous
compounds, such as 2-hydroxybenzoylglycine, that competitively inhibit cefonicid binding to this class of binding site in
neonatal serum and that are not present or are present in
lower concentrations in adult serum (22). Thus, both the
lower binding capacity (NlPA) and the lower binding affinity
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(K1) in neonatal serum result in the lower level of fractional

binding of the antibiotic in this serum than in adult serum.
Cefuroxime protein binding in adult serum was concentration dependent throughout the concentration range tested,
with the percentage bound varying from 88.0% at 25 ,ug/ml to
8.8% at 700 ,ug/ml. Unlike cefonicid, cefuroxime exhibited
concentration-dependent binding in adult serum over the
entire therapeutic range. The extent of fractional binding
found within the therapeutic range (88 to 40%) in the present
study was somewhat greater than the previously reported
values of 50 to 33% (2, 9). This result may be due to the
assessment of cefuroxime protein binding at lower concentrations in the present study. Like cefonicid, cefuroxime was
found to bind to a high-affinity (K1 = 7.1 x 104 M-1),
saturable binding site as well as to a low-affinity (N2K2 = 195
M-1) binding site that was not saturated over the range of
drug concentrations studied. Interestingly, however, the
number of binding sites per albumin molecule was only 0.15.
The number of binding sites on the albumin molecule for
other cephalosporins (19), including cefonicid, has been
shown to be 1. These results suggest that the protein
responsible for the high-affinity binding of cefuroxime may
not be albumin but rather another serum protein. The
binding capacity for this class of binding site was 1.0 x 10-4
M. Another possible explanation for N1 being less than 1 is
that serum contains compounds that noncompetitively inhibit cefuroxime protein binding.
There was a marked contrast between adult and neonatal
sera in the fraction of cefuroxime bound to serum proteins
(Fig. 2). Cefuroxime binding in neonatal serum was concentration independent, averaging 15.6% over the entire concentration range studied. The high-affinity binding site demonstrated in adult serum was not present in neonatal serum.
The relatively low level of constant fractional binding of
cefuroxime in neonatal serum indicates a binding site with a
large capacity but a low affinity. The values for the nonspecific binding parameter, N2K2, were similar for neonatal and
adult sera; thus, the levels of fractional binding at high drug
concentrations, at which the high-affinity binding site is
saturated in adult serum, were similar for both types of sera.
The percentage of cefuroxime bound to neonatal serum
within the therapeutic range was lower than that for adult
serum because of the lack of the high-affinity binding site in
neonatal serum. This result further suggests that albumin is
not the serum protein responsible for the high-affinity binding of cefuroxime in adult serum. The absence of a highaffinity binding site in neonatal serum suggests that the
protein responsible for this binding is not developed in
neonates or that neonatal serum contains an endogenous

compound (22) that competitively inhibits the association of
cefuroxime with protein.
The differences in protein binding of these cephalosporins
between adult and neonatal sera are important for several
reasons. One is the potential for drug interactions. When two
or more molecules compete for the same binding site and the
concentration of one or more of them approaches the saturation point for that particular binding site, the potential for
displacement of one substance by another exists. For drugs
such as the cephalosporins, the large therapeutic concentration range decreases the likelihood of any such interaction
becoming clinically important. However, with substances
such as bilirubin, such an interaction can be potentially
devastating in neonates. In the selection of drugs for use in
neonates, one must consider protein binding and whether
such binding is likely to interfere with the protein binding of
bilirubin. In neonatal serum, cefonicid exhibited saturation
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of binding sites in the therapeutic range. Cefonicid has been
shown to compete with bilirubin for albumin binding sites in
vitro (16). The risk of a clinically significant interaction
occurring between cefonicid and bilirubin in neonates appears high. In contrast, cefuroxime showed no saturation of
protein binding sites at the concentrations studied and would
not therefore be expected to displace bilirubin significantly.
The latter finding has been confirmed by others (16). When a
decision regarding the appropriate antibiotic choice in neonatal infections must be made, it may be prudent to choose
an agent that is less extensively bound to albumin.
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